Introduction {#sec1}
============

Feeding on a high-calorie diet (HCD) causes obesity and diabetes ([@bib33]), which are known cancer risk factors ([@bib2; @bib3; @bib4; @bib10]). Thus, gaining a better understanding of the relationship between increased calorie intake and cancer is urgent, as it will provide insights into the mechanisms of cancer pathogenesis.

Increased anabolic signaling caused by HCD may explain higher cancer risk in obesity ([@bib31]). For example, HCD increases blood levels of anabolic citokines (e.g., insulin, insulin-like growth factors, and leptin) that are known to promote tumor growth and survival by signaling via the PI3K-AKT-mTOR and RAS-MAPK pathways ([@bib1; @bib6; @bib29; @bib32; @bib36]). Another well-established event associated with HCD is the increased inflammatory (e.g., TNF-α) signaling, which is also known to favor tumorigenesis ([@bib20]).

Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) representing almost 85% of all cases. Activating mutations of the proto-oncogene *KRAS* (mutant *KRAS*) occur in ∼30% of NSCLC cases ([@bib25]). Mutant KRAS-driven tumors are associated with an aggressive phenotype, resistance to therapy, and poor outcome ([@bib19]). The results from epidemiological studies assessing the effect of obesity on lung cancer risk are still inconclusive ([@bib3; @bib5; @bib13; @bib35]).Yet, calorie restriction exerts a robust anti-tumor effect on KRAS-driven lung cancer in rodents ([@bib9]), indicating that this type of tumor is sensitive to dietary changes. However, preclinical studies assessing KRAS-driven lung tumorigenesis in the context of increased calorie intake are missing. We reasoned that if HCD feeding interferes with KRAS-driven lung tumorigenesis, then the study of this contextual effect could be exploited to unmask key cancer vulnerabilities. Hence, we assessed the impact of HCD feeding on KRAS-driven lung tumors in mice.

Results {#sec2}
=======

A Dual Effect of Chronic HCD Feeding on KRAS-Driven Lung Tumorigenesis {#sec2.1}
----------------------------------------------------------------------

To comprehensively analyze the effect of HCD feeding on lung tumors in vivo, we fed genetically modified mice that develop KRAS-driven lung tumors (i.e., *Kras*^*G12D*^ mice) with HCD starting before or after tumor onset. *Kras*^*G12D*^ mice were obtained by breeding a transgene encoding *Kras*^*G12D*^ under the control of the tetracycline operator (*Tet-op-Kras*) to a transgene expressing the reverse tetracycline transactivator in the respiratory epithelium under the control of the Clara cell secretory protein promoter (*CCSP-rtTA*). The resulting bi-transgenic *Kras*^*G12D*^ mice develop lung cancer with 100% penetrance following continuous doxycycline (doxy) administration ([@bib7]). The effect of the different dietary treatments on lung tumors was assessed by comparing neoplastic lesion profiles between three groups: (i) *Kras*^*G12D*^ mice constantly fed a standard diet (SD *Kras*^*G12D*^ group), (ii) *Kras*^*G12D*^ mice switched and maintained on a HCD starting 4 weeks after tumor induction (HCD-post-tumor-onset *Kras*^*G12D*^ group), and (iii) *Kras*^*G12D*^ mice switched and maintained on a HCD starting 12 weeks before tumor induction (HCD-pre-tumor-onset *Kras*^*G12D*^ group) ([Figure 1](#fig1){ref-type="fig"}A). In all groups tumorigenesis was induced at the age of 18 weeks by doxy treatment, and endpoint analyses were performed at the age of 29 weeks ([Figure 1](#fig1){ref-type="fig"}A).

HCD-pre-tumor-onset *Kras*^*G12D*^ mice (18 and 29 weeks old) had increased body weight, hyperinsulinemia, and hyperleptinemia, while these parameters were all normal in HCD-post-tumor-onset *Kras*^*G12D*^ mice compared to age-matched SD *Kras*^*G12D*^ mice. However, at the age of 29 weeks both HCD-fed groups displayed increased hepatic lipid accumulation ([Figures S1](#app3){ref-type="sec"}A--S1C, available online).

Strikingly, endpoint analysis of the lungs revealed opposite effects of the two different HCD feeding regimens on neoplastic lesions. The HCD-post-tumor-onset *Kras*^*G12D*^ mice had a significant increase in tumor burden owing to increased tumor size and number, while HCD-pre-tumor-onset *Kras*^*G12D*^ mice had these parameters significantly reduced compared to those of SD *Kras*^*G12D*^ mice ([Figures 1](#fig1){ref-type="fig"}B and 1C). Notably, the tumor burden-, size-, and number-suppressing effect of pretreatment with HCD applied to both genders ([Figures 1](#fig1){ref-type="fig"}B, 1C, and [S1](#app3){ref-type="sec"}D).

Histopathological examination indicated that neoplastic lesions from all groups were adenomas ([Figure 1](#fig1){ref-type="fig"}B).Yet, lesions from HCD-post-tumor-onset *Kras*^*G12D*^ mice were distinguished by the presence of nests of cells containing large atypical nuclei ([Figure 1](#fig1){ref-type="fig"}B), indicating a more advanced tumor grade.

Next, we set out to determine the underlying mechanism of HCD effect on tumor growth. As the tumor formation and maintenance in *Kras*^*G12D*^ mice is strictly dependent on oncogenic *Kras*^*G12D*^ expression ([@bib7]), we measured *Kras*^*G12D*^ mRNA level in tumor lesions. This parameter was similar between groups ([Figure S1](#app3){ref-type="sec"}E), hence ruling out the idea that the different tumor growth observed between groups was the consequence of dietary effects on *Kras*^*G12D*^ expression.

Changes in tumor growth could be the result of altered cellular death, altered cellular proliferation, or both. Notably, while the status of apoptosis markers (assessed by TUNEL assay and immunostaining for cleaved caspase-3) was unchanged ([Figures S1](#app3){ref-type="sec"}F and S1G), the expression levels of proliferation markers (p-H3 and cyclin-D1) were significantly reduced in tumors of HCD-pre-tumor-onset compared to SD *Kras*^*G12D*^ mice ([Figures 1](#fig1){ref-type="fig"}D and [S1](#app3){ref-type="sec"}H). Conversely, cellular proliferation was increased in HCD-post-tumor-onset compared to SD *Kras*^*G12D*^ mice ([Figure 1](#fig1){ref-type="fig"}D). HCD feeding could also impact tumor initiation. For instance, inflammation caused by dietary obesity is an effective tumor promoter in a model of hepatocellular carcinoma ([@bib20]). In addition, recent studies have shown that chronic pancreatitis is required for KRAS-induced pancreatic ductal adenocarcinomas in adult mice ([@bib8]). Therefore, nongenetic events associated with HCD feeding could modulate tumor initiation when the latter is driven by a defined oncogenic mutation including *KRAS* ([@bib8; @bib20]). Notably, lungs of SD or HCD-pre-tumor-onset *Kras*^*G12D*^ mice treated with doxy for 4 weeks had no differences in tumor size and multiplicity ([Figure S1](#app3){ref-type="sec"}I). Combined, these findings indicate that HCD feeding imposed before tumor onset affects tumor progression rather than initiation.

Collectively, our results show that HCD feeding started before or after tumor onset can inhibit or promote KRAS-driven lung tumorigenesis by mechanisms that involve suppression or enhancement of cellular proliferation, respectively.

Chronic HCD Feeding Causes Unresolved ER Stress in KRAS-Driven Lung Tumors {#sec2.2}
--------------------------------------------------------------------------

We uncovered a surprising and potent anti-tumor effect of HCD imposed before tumor onset. This finding prompted us to look for the underlying mechanism because it could unveil key vulnerabilities of KRAS-driven lung tumors. To this end, we first analyzed the activation status of anabolic signaling pathways known to promote tumorigenesis and be altered in the context of increased calorie intake (i.e., AKT, ERK, and STAT3) ([@bib1; @bib6; @bib29; @bib31; @bib32; @bib36]). For instance, chronic HCD feeding induces systemic insulin resistance characterized by reduced insulin/AKT signaling in metabolically relevant tissues ([@bib26]). Thus, reduced AKT signaling in tumors from HCD-pre-tumor-onset *Kras*^*G12D*^ mice could in principle explain the reduced neoplastic growth. However, while we found reduced insulin-induced phosphorylation of AKT, the basal level of phosphorylated AKT and of one of its downstream targets ribosomal protein S6 was similar between tumors of HCD-pre-tumor-onset and SD *Kras*^*G12D*^ mice ([Figures S2](#app3){ref-type="sec"}A and S2B). These data suggest that exacerbated insulin resistance in tumors of HCD-pre-tumor-onset *Kras*^*G12D*^ mice is not sufficient to dampen basal AKT signaling. Also, the status of phosphorylation and thus activation of ERK and STAT3 signaling was unchanged in HCD-pre-tumor-onset compared to SD *Kras*^*G12D*^ mice ([Figure S2](#app3){ref-type="sec"}B).

An expected consequence of chronic HCD feeding is increased inflammatory signaling. Indeed, we found that the serum level of the proinflammatory cytokine interleukin-6 (IL-6) and the mRNA level of intracellular inflammatory readouts (e.g., *Ik-Βα* and *Tnf-α*) were elevated in tumors of HCD-pre-tumor-onset compared to SD *Kras*^*G12D*^ mice ([Figures S2](#app3){ref-type="sec"}C--S2E). Collectively, the aforementioned results suggest that changes in basal AKT, ERK, STAT3, or inflammatory signaling are likely not underlying the antiproliferative effects of nutritional overload on KRAS-driven lung tumors.

Next, we assessed whole-genome expression profile of microdissected lung tumors and found a significantly reduced expression of chaperones in lung tumors of HCD-pre-tumor-onset compared to SD *Kras*^*G12D*^ mice ([Figures 2](#fig2){ref-type="fig"}A and [S2](#app3){ref-type="sec"}F). Several of these chaperones are established or predicted ER residents. ER chaperones are essential for normal protein folding and key components of the ER-induced UPR (UPR^ER^), a cellular mechanism limiting the degree of ER stress due to the accumulation of unfolded proteins in the ER ([@bib34]). Thus, we hypothesized that tumor cells in HCD-pre-tumor-onset *Kras*^*G12D*^ mice may be unable to mount an effective UPR^ER^. To directly address this idea, we further characterized the status of the UPR^ER^ in tumors of these mice. X-box binding protein 1 (XBP1) is an essential component of the UPR, and in response to ER stress it is spliced to produce the nuclear-localized active transcription factor XBP1s ([@bib34]). Similarly, chronic HCD feeding induced *Xbp1* mRNA splicing in lung tumor tissue of HCD-pre-tumor-onset *Kras*^*G12D*^, as indicated by increased and decreased *Xbp1s* and *Xbp1*-unspliced (*Xbp1-u*) mRNAs, respectively ([Figure 2](#fig2){ref-type="fig"}B). However, despite the increased amount of cytosolic XBP1s, the amount of nuclear XBP1s was lower in lung tumors of HCD-pre-tumor-onset compared to SD *Kras*^*G12D*^ mice ([Figure 2](#fig2){ref-type="fig"}C). This result is in line with the reduced mRNA level of the ER chaperones *Erdj4*, *p58ipk*, *Pdia3*, and *Hedj* (which are known transcriptional targets of XBP1s) in tumors of HCD-pre-tumor-onset compared to SD-fed *Kras*^*G12D*^ mice ([Figure 2](#fig2){ref-type="fig"}D). Consistently, protein content of the same chaperones was also reduced ([Figure 2](#fig2){ref-type="fig"}E). Collectively, these results indicate a defective UPR^ER^ in tumors of HCD-pre-tumor-onset mice.

To independently assay ER stress level, we measured the status of several ER stress transducers. Our data show that the phosphorylation level of eukaryotic translational initiation factor 2α (eIF2α), of ER transmembrane kinase/endoribonuclease (RNase) IRE1α, and activation of c-Jun N-terminal kinase (JNK), all of which are found to be increased upon ER stress ([@bib17; @bib18]), were significantly higher in tumors of HCD-pre-tumor-onset compared to SD-fed *Kras*^*G12D*^ mice ([Figure 2](#fig2){ref-type="fig"}F). Notably, increased p-eIF2α is expected to lead to cell-cycle attenuation or even arrest in proliferating cells ([@bib27; @bib28]), a result consistent with reduced tumor proliferation in HCD-pre-tumor-onset *Kras*^*G12D*^ mice ([Figures 1](#fig1){ref-type="fig"}D and [S1](#app3){ref-type="sec"}H).

Interestingly, mRNA level of another component of the UPR^ER^, and a major component of the ER stress-mediated apoptosis pathway, C/EBP homologous protein (CHOP) was downregulated in tumors of HCD-pre-tumor-onset compared to SD *Kras*^*G12D*^ mice ([Figure 2](#fig2){ref-type="fig"}G). These data are consistent with reduced expression of death receptor-5 (*Dr5*) ([Figure S2](#app3){ref-type="sec"}G), a transcriptional target of CHOP and an important mediator of ER-stress-mediated apoptosis ([@bib15]). CHOP regulates ER-stress-induced apoptosis also by repressing *Bcl2* gene expression ([@bib30]) whose expression was similar in tumors of the different dietary groups ([Figure S2](#app3){ref-type="sec"}G), another result that does not support CHOP-induced activation of apoptotic signaling. We suggest that reduced *Chop* expression may explain, at least in part, why unresolved ER stress does not lead to apoptosis in tumors of HCD-pre-tumor-onset *Kras*^*G12D*^ mice.

Healthy lung tissue (tumor free) from HCD-pre-tumor-onset *Kras*^*G12D*^ mice had increased ER stress compared to SD controls, as determined by *Xbp1s*, p-eIF2α, and p-IRE1α level ([Figures S2](#app3){ref-type="sec"}H and S2I). However, the increased nuclear accumulation of XBP1s and the increased expression of ER chaperones and *Chop* ([Figures S2](#app3){ref-type="sec"}J--S2L) indicated normal UPR^ER^ activation in this tissue. Notably, the levels of the aforementioned ER stress and UPR^ER^ activation markers and XBP1s protein contents were not different between tumors from HCD-post-tumor-onset and SD *Kras*^*G12D*^ mice ([Figures S2](#app3){ref-type="sec"}M--S2Q). Altogether, our data indicate a tumor-specific defect in ER chaperone expression in lungs of *Kras*^*G12D*^ mice that strongly depends on the time HCD feeding is initiated relative to tumor onset.

Chaperones are also essential for the mitochondrial-induced UPR (UPR^mt^), a response aimed at maintaining proper protein folding in the mitochondrial matrix ([@bib24]). UPR^mt^ is activated when mitochondrial protein balance is disrupted and is associated with mitochondrial and nuclear gene expression imbalance ([@bib16; @bib24]). Our data show reduced expression of mitochondrial matrix chaperones in tumors of HCD-pre-tumor-onset *Kras*^*G12D*^ mice compared to their lean controls ([Figure S2](#app3){ref-type="sec"}R). However, no changes in the ratio between nuclear DNA-encoded *Atp5a1* and mitochondrial DNA-encoded *Mtco1* ([Figure S2](#app3){ref-type="sec"}S) were observed. Moreover, level of protein carbonylation and expression of detoxification enzymes catalase (*Cat*) and superoxide dismutase 2 (*Sod2*) did not differ between tumors from different dietary groups ([Figures S2](#app3){ref-type="sec"}T and S2U), indicating a similar level of reactive oxygen species. These results suggest that reduced expression of mitochondrial chaperones in tumors of HCD-pre-tumor-onset compared to SD *Kras*^*G12D*^ mice did not cause significant changes in UPR^mt^ and mitochondrial function; hence, it is not likely to be the reason for the anti-tumor effect of HCD feeding.

Collectively, our data indicate that HCD feeding started before tumor onset causes impaired UPR^ER^ response and consequentially unresolved ER stress in KRAS-driven lung tumors.

Treatment with Chemical Chaperones Reverses the Anti-Tumor Effect of HCD Feeding on KRAS-Driven Lung Tumors {#sec2.3}
-----------------------------------------------------------------------------------------------------------

Our results prompted us to directly test whether the anti-tumor action of HCD on KRAS-driven lung tumors is the result of unresolved ER stress. If unresolved ER stress underlies the antiproliferative effect of HCD feeding, its rescue in HCD-pre-tumor-onset *Kras*^*G12D*^ mice should boost tumor growth to a level similar to that of SD *Kras*^*G12D*^ mice. Administration of chemical chaperones, such as taurorsodeoxycholic acid (TUDCA) or 4-phenyl butyric acid (4-PBA), resolves ER stress induced by increased calorie intake ([@bib18]). Thus, we tested whether treatment with TUDCA or 4-PBA reverses the anti-tumor action of HCD on Kras-driven lung tumors.

During the last 2 weeks of doxy treatment, HCD-pre-tumor-onset *Kras*^*G12D*^ mice were additionally treated daily with TUDCA (or saline) ([Figure 3](#fig3){ref-type="fig"}A). While tumor burden was again significantly reduced in saline-injected HCD-pre-tumor-onset compared to SD *Kras*^*G12D*^ mice, it was comparable between these groups following TUDCA administration ([Figures 3](#fig3){ref-type="fig"}B and 3C). The increased tumor burden in TUDCA-injected HCD-pre-tumor-onset *Kras*^*G12D*^ mice was the result of increased tumor size, but not tumor number ([Figure 3](#fig3){ref-type="fig"}C). Tumor burden, number, and size were not affected by TUDCA administration in SD *Kras*^*G12D*^ mice ([Figures 3](#fig3){ref-type="fig"}B and 3C). Pharmacokinetic assessments revealed a similar level of TUDCA accumulation in lung tumors between the different dietary groups ([Figures S3](#app3){ref-type="sec"}A and S3B). Moreover, the treatment of HCD-pre-tumor-onset *Kras*^*G12D*^ mice with TUDCA resulted in attenuation of ER stress to a level similar to that of SD *Kras*^*G12D*^ mice, as evidenced by expression of ER stress markers ([Figures 3](#fig3){ref-type="fig"}D, 3E, and [S3](#app3){ref-type="sec"}C). These effects were not secondary to changes in body weight, insulinemia, and leptinemia, as these parameters were not different between TUDCA-treated and saline-treated HCD-pre-tumor-onset *Kras*^*G12D*^ mice (data not shown). In line with the fact that chronic HCD feeding caused reduced cellular proliferation ([Figures 1](#fig1){ref-type="fig"}D and [S1](#app3){ref-type="sec"}H), TUDCA reversed the antiproliferative effect of chronic HCD pretreatment on KRAS-driven lung tumors, as indicated by increased expression of p-H3 ([Figure 3](#fig3){ref-type="fig"}F). Notably, the tumor-proliferating effect of TUDCA was not associated with changes in mitochondrial:nuclear gene expression ratio ([Figure S3](#app3){ref-type="sec"}D) or in protein carbonylation level ([Figure S3](#app3){ref-type="sec"}E).

Similar treatment with another structurally unrelated chemical chaperone 4-PBA ([Figure S3](#app3){ref-type="sec"}F) essentially reproduced the effect of TUDCA by relieving ER stress and partially rescuing proliferation and growth of tumors of HCD-pre-tumor-onset *Kras*^*G12D*^ mice ([Figures S3](#app3){ref-type="sec"}G--S3I and data not shown).

Altogether, our data indicate that chronic HCD feeding impairs UPR^ER^ and consequently causes unresolved ER stress that hinders the growth of *Kras*^*G12D*^-driven lung tumors.

Unraveling FKBP10 as a Target for KRAS-Driven Lung Cancer {#sec2.4}
---------------------------------------------------------

Our data suggest that the inhibition of ER chaperones whose expression is negatively affected by HCD pretreatment may represent an effective antiproliferative therapeutic avenue against KRAS-driven lung cancer. A major drawback of current treatments against KRAS-driven lung cancer is the toxic side effects of the drugs due to the lack of selectivity between cancer and normal cells. Therefore, we reasoned that an ideal target against KRAS-driven lung cancer could be an ER chaperone expressed in tumor lesions but not healthy parenchyma.

In order to determine a candidate target, we analyzed our microarray data searching for chaperones that are (i) a resident of the ER, (ii) significantly downregulated in tumors of HCD-pre-tumor-onset Kras^G12D^ mice compared to SD controls, and (iii) specifically expressed in tumor lesions. We found several ER chaperones downregulated in tumors of HCD-pre-tumor-onset *Kras*^*G12D*^ mice ([Figure S2](#app3){ref-type="sec"}F). One of them, namely FKBP10, has been reported not to be expressed in lung during adulthood ([@bib14; @bib23]). Our data indicate that FKBP10 is (i) expressed in tumors of Kras^G12D^ mice, (ii) reduced in tumors of HCD-pre-tumor-onset mice compared to their SD controls, and (iii) barely detectable in normal lung parenchyma ([Figure 4](#fig4){ref-type="fig"}A). Therefore, FKBP10 could be an ideal cancer-selective target against Kras-driven lung tumorigenesis. To our knowledge, the role of FKBP10 in tumorigenesis is unknown.

Next, we assessed the significance of FKBP10 in human lung cancer cell lines and found that it is required for proliferation of lines bearing *KRAS* mutation or mutations different from *KRAS* (i.e., *EGFR* or *PI3K* oncogenic mutations) ([Figures 4](#fig4){ref-type="fig"}B and 4C). Our in vivo data also show that knockdown of FKBP10 is sufficient to hinder tumor growth ([Figure 4](#fig4){ref-type="fig"}D). This anti-tumor effect is caused by reduced cellular proliferation, as determined by reduced cyclin-D1 and p-H3 ([Figures 4](#fig4){ref-type="fig"}E and [S4](#app3){ref-type="sec"}A), and not an increased rate of apoptosis ([Figure S4](#app3){ref-type="sec"}B). Notably, our data indicate that the antiproliferative effect of FKBP10 knockdown is not restricted to lung cancer cell lines but extends to cancer cells derived from other tissues (i.e., breast and pancreas) ([Figures S4](#app3){ref-type="sec"}C and S4D).

To add translational value to our preclinical studies, we assessed expression of FKBP10 in surgically collected human lung samples containing tumor lesions and healthy parenchyma. Importantly, our results indicate that FKBP10 is expressed in KRAS-positive and -negative lung carcinoma, but not in healthy lung parenchyma ([Figures 4](#fig4){ref-type="fig"}F and 4G). Collectively, our data suggest that inhibition of FKBP10 is a promising avenue to selectively hinder lung cancer growth while sparing healthy lung tissue function.

Discussion {#sec3}
==========

Our data challenge the common wisdom that HCD feeding exerts only deleterious effects. In fact, we demonstrate that if HCD starts before tumor onset it dampens growth of KRAS-driven lung tumors ([Figures 1](#fig1){ref-type="fig"}A--1C). However, an opposite outcome is caused by HCD starting after tumor onset ([Figures 1](#fig1){ref-type="fig"}A--1C). Hence, the anti-tumor effect is not due to the diet per se but depends on when HCD feeding is initiated relative to tumor onset.

Our results indicate that impaired UPR^ER^ underlies, at least in part, the anti-tumor action of HCD imposed before tumor onset. We suggest that a contributor to impaired UPR^ER^ is the poor cytosol-to-nucleus translocation of XBP1s, a defect consistent with insulin resistance in tumors of HCD-pre-tumor-onset compared to SD *Kras*^*G12D*^ mice ([Figure S2](#app3){ref-type="sec"}A) ([@bib12; @bib21; @bib22]). Additional studies are needed to test this possibility.

Why does HCD feeding imposed before tumor onset hinder tumor progression but not tumor initiation ([Figures 1](#fig1){ref-type="fig"}B, 1C, and [S1](#app3){ref-type="sec"}I)? We propose that this could be explained, at least in part, by an effect of the HCD on tumor vascularization, as CD31-positive cells were found to be diminished in tumors of HCD-pre-tumor-onset mice compared to the SD *Kras*^*G12D*^ mice (G.R., G.K., and R.C. unpublished data). In fact, this difference may not lead to relevant effects at the initial stage of the tumorigenesis (when tumor lesions are sufficiently vascularized by the vessels in the parenchyma) but may become a limiting factor for further tumor progression, a hypothesis that warrants future experimental testing.

The clinical relevance of our results is at least 2-fold. First, our data suggest that inhibition of chaperones downregulated by HCD pretreatment (e.g., FKBP10) may reduce KRAS-driven lung tumor growth. Second, our data suggest that TUDCA or PBA treatment improves ER stress, therefore leading to increased growth of already-formed KRAS-driven lung tumors in the context of obesity. Because TUDCA and PBA are currently undergoing evaluation (<http://clinicaltrials.gov> identifiers: NCT00771901, NCT01877551) on insulin-resistant subjects (a population typically also affected by increased body adiposity), our results caution for evaluation of cancer risk in these patients.

It is important to note that we have studied the effects of relatively short-term HCD on KRAS-driven lung tumors. Thus, long-term outcomes and the contribution of obesity and/or other metabolic defects caused by HCD to tumor behavior remain to be evaluated. Also, while our pharmacological data shown in [Figures 3](#fig3){ref-type="fig"}A--3F and [S3](#app3){ref-type="sec"}A--S3I suggest that unresolved ER stress underlies reduced tumor growth in HCD-pre-tumor-onset *Kras*^*G12D*^ mice, further genetic studies will be needed to fully dissect the underpinning mechanisms. Lastly, our data warrant thorough epidemiological assessment of lung cancer risk in obese people.

In summary, we unveiled an anti-tumor effect of HCD feeding on KRAS-driven lung tumorigenesis. Unresolved ER stress owing to impaired UPR^ER^ underlies, at least in part, the anti-tumor action of HCD. Hence, we propose that this vulnerability of KRAS-driven lung tumors could be targeted for therapeutic purposes. Importantly, we also identified FKBP10 as a putative anti-cancer target.

Experimental Procedures {#sec4}
=======================

Mouse Generation and Studies {#sec4.1}
----------------------------

*CCSP-rtTA/Tet-op-K-ras* mice (FVB/SV129 mixed background) were generated as previously described ([@bib11]) and housed in groups of 4--5 with food (either SD or HCD; D12331 from Research Diets) and water available ad libitum in light- and temperature-controlled environments. Drinking water was supplemented with doxycycline at the concentration of 200 μg/ml. TUDCA was administered by intraperitoneal injection (250 mg/kg at 8 a.m. and 250 mg/kg at 8 p.m.). 4-PBA was administered at the same time points (500 mg/kg) by oral gavage. Care of mice at UTSW Medical Center at Dallas and at University of Geneva was within the procedures approved by Institutional Animal Care and Use Committee and by the animal care and experimentation authorities of the Canton of Geneva, respectively. Xenograft experiments were performed by subcutaneous inoculation of cells into 8-week-old male SCID mice.

Immunoblotting, Immunohistochemistry, and Quantitative Real-Time PCR {#sec4.2}
--------------------------------------------------------------------

These procedures were performed as previously described ([@bib11]). Clinical data were collected at Università Politecnica delle Marche from samples from patients who signed a waiver of authorization.

Expression Profiling {#sec4.3}
--------------------

Gene expression profiles were obtained from microdissected lung tumors using MouseWG-6 v2.0 Expression BeadChips (Illumina).

shRNAs, Virus Production, and Transduction of Cell Lines {#sec4.4}
--------------------------------------------------------

pLKO vectors (Open Biosystems) were used to produce recombinant lentiviruses using TransIT-293T Mirus reagent following manufacturer's instructions. Human cell lines A549, H596, H1650, ASPC, and MDA-MB231 were transduced as previously described ([@bib11]).

Carbonylated Protein Determination {#sec4.5}
----------------------------------

Levels of carbonylated proteins were determined by ELISA (Enzo Life Sciences) following manufacturer's instructions.

Pharmacokinetics Assessments {#sec4.6}
----------------------------

Analytical assay of plasma, lung, and tumor samples was performed using a QTRAP 4000 LC-MS/MS system.

Statistical Analysis {#sec4.7}
--------------------

Two-tail unpaired Student's t test or one-way ANOVA (Tukey's post test) was used when comparing two groups or more than two groups, respectively. Error bars represent SEM.

Author Contributions {#sec5}
====================
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![A Dual Effect of Chronic HCD Feeding on KRAS-Driven Lung Tumorigenesis\
(A) Timetable of mouse treatments.\
(B) Representative images of lung sections stained with hematoxylin and eosin (H&E) (inserts indicate area selected by arrows for higher magnification images; asterisk indicates the presence of nests of cells with large atypical nuclei).\
(C) Histograms showing quantification of tumor burden, size, and number.\
(D) Representative images of lung sections stained with anti-p-H3 (p-H3-positive cells in dark brown) and histograms indicating the percentage of p-H3-positive cells/tumor cells.\
Data shown in (B)--(D) are from 29-week-old *Kras*^*G12D*^ mice treated as in (A) (females, n = 6--7/ group). Error bars represent SEM. Statistical analyses were done using one-way ANOVA (Tukey's post test). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S1](#app3){ref-type="sec"}.](gr1){#fig1}

![Unresolved ER Stress in Lung Tumors of HCD-Pre-Tumor-Onset *Kras*^*G12D*^ Mice\
(A) Gene set enrichment analysis (GSEA) plot showing chaperone enrichment score depicted by NES and nominal p value (the gene set used for GSEA is GO: 0006457).\
(B) *Xbp1s* and *Xbp1u* mRNA levels.\
(C) Immunoblot images and quantifications of cytosolic and nuclear XBP1 protein content (Lamin A and Tubulin were used as nuclear and cytosolic markers, respectively).\
(D) mRNA levels of ER chaperones.\
(E) Immunoblot images and quantification of ER chaperone protein content in total cell lysate.\
(F) Immunoblot images and quantification of the phosphorylation status of eIF2α, IRE1α, and c-JUN.\
(G) *Chop* mRNA levels.\
All panels show data from microdissected lung tumors of 29-week-old *Kras*^*G12D*^ males treated as described in [Figure 1](#fig1){ref-type="fig"}A (n = 5--6/group). Error bars represent SEM. Statistical analyses were done using two-tailed unpaired Student's t test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S2](#app3){ref-type="sec"}.](gr2){#fig2}

![TUDCA Treatment Reverses the Anti-Tumor Effect of HCD Feeding on KRAS-Driven Lung Tumors\
(A) Timetable of mouse treatments.\
(B) Representative images of lung sections stained with H&E.\
(C) Histograms indicating quantification of tumor burden, size, and number.\
(D) mRNA levels of *Xbp1s*.\
(E) Representative immunoblot against phospho- and total IRE1α and eIF2α.\
(F) Representative images of lung sections stained with anti-p-H3 (p-H3-positive cells in brown) and histograms indicating the percentage of p-H3-positive cells/tumor cells of microdissected tumors.\
Data shown in (B)--(F) are from 29-week-old *Kras*^*G12D*^ mice treated as indicated in (A) (females, n = 5/group). Error bars represent SEM. Statistical analyses were done using one-way ANOVA (Tukey's post test). ^∗^p \< 0.05, ^∗∗^p \< 0.01. See also [Figure S3](#app3){ref-type="sec"}.](gr3){#fig3}

![Unraveling FKBP10 as a Therapeutic Target for KRAS-Driven Lung Cancer\
(A) Expression of FKBP10 in lung tumors of 29-week-old *Kras*^*G12D*^ mice treated as in [Figure 1](#fig1){ref-type="fig"}A (males, n = 5--6/group) (as negative control \[−\], we loaded a similar amount of lysate from wild-type lung tissue).\
(B) Knockdown in A549 cells (*KRAS* mutation) of FKBP10 using five different shRNAs and relative proliferation curves.\
(C) Antiproliferative effect of FKBP10 knockdown in H1650 (*EGFR* mutation) and A596 (*PI3K* mutation) cell lines.\
(D) Xenograft growth of A549 cells in SCID mice injected subcutaneously with 1 × 10^6^ cells as indicated (n = 5 for group).\
(E) Immunoblot from tumors of mice treated as indicated in (D).\
(F) Representative images of a human lung section stained against FKBP10 ("L" indicates tumor-free lung parenchyma; "T" indicates lung tumor lesion).\
(G) Table indicating the expression of FKBP10 in human specimens including tumor lesions and adjacent tumor-free tissue. Error bars represent SEM. Statistical analyses were done using two-tailed unpaired Student's t test or using one-way ANOVA (Tukey's post test). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S4](#app3){ref-type="sec"}.](gr4){#fig4}
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